1Snodin DT. Toxicology and adverse Drug Reactions[ A]. In: Talbot J, Waller B, eds. Stephen's detection of new adverse drug reaction [M]. 5th ed. Chichester West Sussex: John Wiley & Sons. Ltd,2004:127 - 166.
2Li AP. Accurate prediction of human drug toxicity: a major challenge in drug development[J]. Chem Biol Interact, 2004, 150(1):3- 7.
3Yamamoto Y, Yamazaki H, Ikeda T, et al. Formation of a novel quinone epoxide metabolite of troglitazone with cytotoxic to HepG2cells[J]. Drug Metab Dispos, 2002, 30(2): 155 - 160.
4Boelsterli UA. Xenobiotic acyl glucuronides and acyl CoA thioesters as protein-reactive metabolites with the potential to cause idiosyncratic drug reaction[J]. Curr Drug Metab , 2002, 3(4):439-450.
5Squella JA, Gonzalez P, Bollo S, et al. Electrochemical generation and interaction study of nitro radical anion from nimesulide [ J ].Pharm Res, 1999, 16(1):161 - 164.
6Greaves RR, Agarwal A, Patch D, et al. Inadvertent diclofenac rechallenge from generic and non-generic prescribing leading to liver transplantation for fulminant liver failure [ J ]. Eur J Gastroenterol Hepatol, 2001, 13(1) :71 - 73.
7Smith MT. Mechanisms of troglitazone hepatotoxicity[ J]. Chem Res Toxicol, 2003, 16(6) :679 - 687.
8Bugelski PJ. Genetic aspects of immune-mediated adverse drug effects[J]. Nat Rev Drug Discov, 2005, 4(1) :59 - 69.
9Roth RA, Luyendyk JP, Maddox JF, et al. Inflammation and drug idiosyncrasy- is there a connection [ J ] ? J Pharmacol Exp Ther,2003, 307(1):1-8.
10Boelsterli UA. Diclofenac-induced liver injury: a paradigm of idiosyncratic drug toxicity [ J ]. Toxicol Appl Pharmacol, 2003, 192(3) :307 - 322.
